Novartis Ag

University of Pennsylvania

University of Pittsburgh

Laura Alexandra Johnson

Carl H June

Andreas Loew

Jennifer Brogdon

Marcela V Maus

John Scholler

Hideho Okada

Danielle Cook

The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

The present invention relates to compositions and methods for using a minibody. Minibodies described herein comprise a secretion signal, a variable heavy chain fragment, a variable light chain fragment, a constant chain fragment, and a hinge domain between the variable light chain fragment and the constant chain fragment. One aspect includes a nucleic acid encoding a minibody. Other aspects include compositions comprising a minibody and a modified T cell comprising a nucleic acid encoding a minibody. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy and treating a condition, such as cancer.

Cell secreted minibodies and uses thereof

Growing community of inventors

Ardmore, PA, United States of America

Laura Alexandra Johnson